Chemokine Therapeutics Receives Approval for Human Clinical Trial for its Anti Cancer Drug
Chemokine Therapeutics Corp. announced that it has received approval from Health Canada to initiate a phase Ib/II clinical trial using CTCE-9908, a chemokine CXCR4 antagonist. With this notice, the Company is now in a position to initiate the clinical trial. The Company plans to test the drug in approximately up to 30 patients with late stage cancers to evaluate safety as well as early efficacy. The trial is designed to study a mixed group of tumors that will include the most common cancers such as ovarian, lung, and breast.
Chemokine expects to expand its CTCE-9908 clinical program with the filing of an IND to the FDA in the first quarter of this year. In previous preclinical studies, CTCE-9908 has been shown to reduce cancer metastases by 50-70% and to have anti-angiogenic properties. In July of 2005, the United States Food and Drug Administration (FDA) granted orphan-drug designation to CTCE-9908 for the treatment of osteogenic sarcoma, a bone cancer that occurs in children and young adults.
CTCE-9908 is designed to block the receptor (CXCR4) that has been identified as critical in the process of tumor metastasis to other tissues in the body. The CXCR4 receptor is present on most human tumors cells, including lung, breast, prostate, colon, ovarian, bone, brain, and skin cancer. Leading cancer researchers have demonstrated that a high level of CXCR4 expression in cancer cells is correlated to tumor progression, high metastasis rate and low patient survival rate.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
